(Reuters) - But the new submission includes efficacy data showing some protection against additional cervical cancer-causing HPV types, and data on protection against vaginal and vulvar cancers.
The filing with the European Medicines Agency follows a similar submission to the U.S. Food and Drug Administration last week.
Read more at Reuters.com Government Filings News
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment